Malaria in India: Elimination Framework 2030, Vectors, Vaccines & Hotspots

!Anopheles stephensi mosquito feeding

Malaria in India is a vector-borne parasitic disease that has been with the subcontinent for at least three millennia and remains entrenched in pockets of the Northeast, central tribal belt and eastern coast. India reported around 227,000 confirmed malaria cases and 83 deaths in 2023 — down from a peak of about 75 million cases at the time of independence and around 2 million cases as recently as 2000. The decline is one of the steepest in the world, and the World Health Organization’s World Malaria Report 2024 recognises India as having moved out of the top three highest-burden countries globally for the first time. Yet roughly 80 per cent of India’s population still lives in malaria-receptive zones, and the goal of full elimination by 2030 remains demanding.

The National Framework for Malaria Elimination 2016-2030 (NFME), released by the Ministry of Health and Family Welfare in February 2016, is the policy spine. It commits India to interrupting transmission across the country by 2027 and achieving certified malaria-free status by 2030. Malaria in India is implemented under the National Vector Borne Disease Control Programme (now folded into the National Centre for Vector Borne Diseases Control, NCVBDC) and runs in close partnership with the WHO South-East Asia Region’s E-2025 initiative for low-burden countries.

Parasitology: The Plasmodium Species

Human malaria is caused by single-celled protozoan parasites of the genus Plasmodium. Five species infect humans: P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi (a zoonotic species from macaques, now recognised across South-East Asia). India sees mainly two:

Plasmodium falciparum

Plasmodium falciparum causes the most severe form of malaria — cerebral malaria, severe anaemia, acute respiratory distress and multi-organ failure — and accounts for almost all malaria deaths. It now constitutes around 65 per cent of confirmed cases in India, predominantly in the Northeast, central India and the eastern coast. Severe falciparum malaria is a medical emergency requiring parenteral artesunate.

Plasmodium vivax

Plasmodium vivax causes less acutely fatal disease but is harder to eliminate because it forms dormant liver-stage hypnozoites that can relapse months or years after the primary infection. Vivax accounts for the bulk of the remaining cases and is concentrated in urban and peri-urban India, Rajasthan, Gujarat, Haryana and Punjab. Radical cure requires a 14-day course of primaquine — or the single-dose tafenoquine, recommended by WHO since 2018 — after G6PD-deficiency screening.

Other Species

P. malariae and P. ovale are rare in India, contributing well under 1 per cent of cases combined. P. knowlesi has been reported sporadically from the Andaman and Nicobar Islands.

The Anopheles Vector

Malaria is transmitted by the bite of a female Anopheles mosquito. Of the roughly 60 Anopheles species in India, six are recognised vectors of public-health importance.

Major Vectors

• Anopheles culicifacies — the principal rural vector across the Indian plains, breeds in rice fields, irrigation channels and rain pools.
• Anopheles stephensi — the principal urban vector, breeds in overhead tanks, wells, construction sites and is now spreading aggressively in African cities.
• Anopheles fluviatilis — important in foothill and forested terrain in the Northeast, Odisha and central India.
• Anopheles minimus — historically important in the Northeast and Eastern Himalayan foothills.
• Anopheles dirus — a forest vector in the Northeast, particularly Arunachal Pradesh.
• Anopheles sundaicus — a coastal vector in the Andaman and Nicobar Islands.

Vector Control

NCVBDC vector control rests on indoor residual spraying (IRS) with synthetic pyrethroids in high-burden villages, long-lasting insecticidal nets (LLINs) distributed free of cost in tribal and Northeast districts, larvivorous fish (Gambusia and Poecilia), source reduction and personal protection. India had distributed over 70 million LLINs by 2024, with priority to the seven Northeast states, Odisha, Jharkhand, Chhattisgarh, Madhya Pradesh and tribal districts of Maharashtra and Andhra Pradesh.

National Framework for Malaria Elimination 2016-2030

The NFME divides India’s 36 states and union territories into four categories based on annual parasite incidence (API): Category 0 (free of indigenous transmission), Category 1 (API less than 1 per 1,000), Category 2 (API 1 to less than 2) and Category 3 (API 2 and above). The framework’s goals are progressive: by 2022, malaria elimination in all Category 1 states; by 2024, in all Category 2; by 2027, interruption of transmission nationally; by 2030, certified malaria-free.

Progress to 2024

By 2024, all 36 states and UTs are below an API of 1 per 1,000 — a historic milestone. Twenty-five states and UTs have reported zero indigenous P. falciparum cases over the most recent three-year window. Active foci of transmission are now concentrated in fewer than 25 high-burden districts, primarily in Odisha, Chhattisgarh, Jharkhand, Mizoram, Tripura and the West Singhbhum region. India is now classified by WHO as a low-burden country and is preparing to apply for malaria-elimination certification later in the 2020s, provided three consecutive years of zero indigenous cases are achieved nationwide.

Malaria Vaccines

After more than three decades of development, two malaria vaccines have been recommended by the WHO since 2021. Neither is yet part of India’s routine immunisation programme, but their availability has changed the global elimination conversation.

RTS,S/AS01 (Mosquirix)

RTS,S, developed by GlaxoSmithKline and the PATH Malaria Vaccine Initiative, was the first malaria vaccine recommended by WHO, in October 2021. It targets the circumsporozoite protein of P. falciparum and is administered as a four-dose schedule to children from six months. Efficacy is moderate — around 36 per cent against clinical malaria over four years — but the public-health benefit in high-transmission African settings is substantial. RTS,S is not used in India because P. falciparum is no longer the dominant species in most states and routine inclusion is not cost-effective at current incidence.

R21/Matrix-M

R21/Matrix-M, developed by the Jenner Institute at Oxford and manufactured at scale by the Serum Institute of India in Pune, was recommended by the WHO in October 2023 — a landmark moment for Indian vaccine manufacturing. R21 uses the same antigen as RTS,S but with the proprietary Matrix-M adjuvant; efficacy in Phase III trials exceeded 75 per cent in highly seasonal settings. R21 is being deployed across more than a dozen African countries from 2024 onwards. India does not use it routinely but supplies the global rollout through SII.

Why India Has Not Adopted Routine Malaria Vaccination

Routine malaria vaccination in India is not currently recommended because indigenous P. falciparum transmission is already low and falling, vaccine efficacy against P. vivax — the dominant species in much of India — is unproven, and the cost-effectiveness of vaccination is poor at current case numbers. India’s strategy is to maintain vaccines as a contingency tool for outbreak response.

Hotspots and High-Burden States

Three geographic clusters carry the bulk of India’s remaining malaria burden.

Northeast India

The seven Northeast states — particularly Mizoram, Tripura, Meghalaya and Arunachal Pradesh — have historically had India’s highest API. Forest fringes, jhum cultivation, low LLIN coverage and porous international borders sustain transmission. Mizoram and Tripura have made dramatic recent gains and are approaching elimination.

Central India Tribal Belt

Odisha, Chhattisgarh, Jharkhand and Madhya Pradesh together account for more than half of India’s remaining cases. The Kalahandi-Balangir-Koraput region of Odisha and the Sukma-Bijapur-Dantewada belt of Chhattisgarh remain the largest individual reservoirs. The Durgam Anchalare Malaria Nirakaran (DAMaN) campaign, run by the Odisha government in remote tribal villages since 2017, has been credited with cutting Odisha’s malaria burden by over 90 per cent in eight years.

Urban Pockets

Urban P. vivax malaria persists in Mumbai, Delhi, Ahmedabad, Bengaluru and Hyderabad, driven by construction sites, overhead tanks and water-storage practices in informal settlements. Anopheles stephensi, the urban vector, breeds in stored fresh water and is increasingly insecticide-resistant. The wider urban public health architecture and the one-health approach shape long-term urban control.

Insecticide-Treated Bednets and Personal Protection

Long-lasting insecticidal nets are the single most cost-effective malaria-control intervention. NCVBDC distributes LLINs free of charge in API-2-and-above villages on a roughly three-year replacement cycle. The current generation of nets uses dual-insecticide formulations — typically a pyrethroid combined with chlorfenapyr or piperonyl butoxide — to counter mounting pyrethroid resistance in Anopheles culicifacies and Anopheles stephensi. Community uptake remains a constraint; coverage exceeds 90 per cent in the Northeast but is far lower in some tribal districts of central India.

Diagnostics and Treatment

Bivalent rapid diagnostic test kits (Pf-Pv RDTs) are deployed across more than 8 lakh ASHA, sub-centre and primary health centre sites. Microscopy remains the gold standard at higher levels. First-line treatment is artesunate-sulfadoxine-pyrimethamine (AS-SP) for P. falciparum in most states, switched to artemether-lumefantrine (AL) in the Northeast since 2013 because of SP resistance. P. vivax is treated with chloroquine plus a 14-day primaquine course for radical cure. Severe malaria of any species is treated with intravenous artesunate.

Malaria in India for UPSC

Malaria in India is a recurring topic in UPSC General Studies Paper II (health) and Paper III (science and technology). Candidates should know that P. falciparum now accounts for about 65 per cent of confirmed cases, that Anopheles culicifacies is the principal rural vector and Anopheles stephensi the principal urban vector, that the National Framework for Malaria Elimination 2016-30 targets certified malaria-free status by 2030, that R21/Matrix-M is manufactured in India by the Serum Institute and was recommended by WHO in October 2023, and that India is now classified by WHO as a low-burden country with API below 1 across all states.

Frequently Asked Questions